Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features
- Authors
- Yoo, Kwai Han; Yoon, Dok Hyun; Kang, Hye Jin; Lee, Won Sik; Kim, Kihyun; Kim, Jin Seok; Kim, Jeong-A; Kim, Sung-Hyun; Kwak, Jae-Yong; Kim, Yang Soo; Min, Chang-Ki; Lee, Je-Jung; Yoon, Sung-Soo; Suh, Cheolwon; Baz, Rachid; Lee, Jae Hoon
- Issue Date
- Feb-2022
- Publisher
- MOSBY-ELSEVIER
- Keywords
- Corticosteroids; Lenalidomide; Myeloma; Older adults; Response-adapted therapy
- Citation
- Current Problems in Cancer, v.46, no.1
- Journal Title
- Current Problems in Cancer
- Volume
- 46
- Number
- 1
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83829
- DOI
- 10.1016/j.currproblcancer.2021.100788
- ISSN
- 0147-0272
- Abstract
- Lenalidomide and low-dose dexamethasone (Rd) are a standard treatment for older adults with multiple myeloma (MM). Lenalidomide monotherapy has rarely been evaluated for newly diagnosed transplant-ineligible MM patients. This multicenter phase II trial evaluated a response-adapted strategy for elderly patients with newly diagnosed MM without high-risk features. Patients were administered single-agent lenalidomide for the first 21 days of two 28-day cycles. Patients with progressive disease received Rd. The primary endpoint was progression-free survival using the uniform response assessment from the International Myeloma Working Group. Of the 34 enrolled patients, 28 were included in the efficacy analysis. The overall response rate (ORR, ≥ partial response [PR]) to single-agent lenalidomide or lenalidomide plus prednisone was 64.3%. Ten patients received Rd after disease progression, with an Rd ORR of 70%. The ORR of response-adapted lenalidomide-based therapy was 75%. After the median follow-up of 35.6 months, the median progression-free survival was 33.5 months (95% confidence interval [CI], 16.9-50.2), and the median overall survival was 51.8 months (95% CI, 22.0-81.6). The most common adverse event was neutropenia (46.7%), and 17 patients (56.7%) experienced infection including pneumonia. Response-adapted lenalidomide-based therapy was feasible in newly diagnosed, transplant-ineligible MM patients without high-risk features. © 2021
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83829)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.